| 标题 |
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia |
| 网址 | |
| DOI | |
| 其它 |
期刊:Applied Health Economics and Health Policy 作者:Carsten Hirt; Sergio Iannazzo; Silvia Chiroli; Lisa J. McGarry; Philipp le Coutre; et al 出版日期:2019-06-06 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)